We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA approved a second gene therapy for cancer, adding Kite Pharma’s lymphoma treatment Yescarta (axicabtagene ciloleucel) to the fledgling list. Read More
An Atlanta federal judge found several individuals and their two firms in contempt for violating court orders over the sale of deceptively marketed weight-loss supplements, imposing a judgement of more than $40 million. Read More
Sen. Claire McCaskill (D-Mo.) introduced a bill that would repeal 2016 legislation that she believes weakened the Drug Enforcement Administration’s ability to go after opioid distributors. Read More
A shift to more expensive settings can mean higher costs for Medicare beneficiaries and privately insured patients who pay a portion of the treatment charges. Read More
The judge said the claim that bupropion is an obvious choice for further investigation as a weight loss treatment derives from “impermissible hindsight bias.” Read More